Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Experimental Neurology

• Publication date

  2007-11-01

• Fields of study

  Biology, Medicine, Psychology

• Identifiers
  DOI 10.1016/J.EXPNEUROL.2007.07.021PMID 17900568PMCID PMC2128772
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models

  2007cited by this paper
• Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine.

  2006cited by this paper
• Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease?

  2006cited by this paper
• Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain.

  2006influential reference
• Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications.

  2006cited by this paper
• Motor complications in Parkinson's disease and the clinical significance of rotational behavior in the rat: have we wasted our time?

  2006influential reference
• Role of striatal l‐DOPA in the production of dyskinesia in 6‐hydroxydopamine lesioned rats

  2006cited by this paper
• Post‐ versus presynaptic plasticity in L‐DOPA‐induced dyskinesia

  2006influential reference
• Loss of Synaptic D1 Dopamine/N-Methyl-d-aspartate Glutamate Receptor Complexes in l-DOPA-Induced Dyskinesia in the Rat

  2006cited by this paper
• A Critical Interaction between NR2B and MAGUK in l-DOPA Induced Dyskinesia

  2006cited by this paper
• Endothelial Proliferation and Increased Blood–Brain Barrier Permeability in the Basal Ganglia in a Rat Model of 3,4-Dihydroxyphenyl-l-Alanine-Induced Dyskinesia

  2006cited by this paper
• A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats.

  2006cited by this paper
• Quantification of endocannabinoids in rat biological samples by GC/MS: technical and theoretical considerations.

  2006cited by this paper
• The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin.

  2006cited by this paper
• Characterization of the Fatty Acid Amide Hydrolase Inhibitor Cyclohexyl Carbamic Acid 3′-Carbamoyl-biphenyl-3-yl Ester (URB597): Effects on Anandamide and Oleoylethanolamide Deactivation

  2005cited by this paper
• Evidence for novel cannabinoid receptors.

  2005cited by this paper
• Transient Receptor Potential Vanilloid Subtype 1 Mediates Cell Death of Mesencephalic Dopaminergic Neurons In Vivo and In Vitro

  2005cited by this paper
• Expression and distribution of vanilloid receptor 1 (TRPV1) in the adult rat brain.

  2005cited by this paper
• A role for endocannabinoids in the generation of parkinsonism and levodopa‐induced dyskinesia in MPTP‐lesioned non‐human primate models of Parkinson's disease

  2005cited by this paper
• Distribution of cannabinoid receptors in the central and peripheral nervous system.

  2005cited by this paper
• The origin of motor fluctuations in Parkinson’s disease

  2004cited by this paper
• Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.

  2004cited by this paper
• Cannabis for dyskinesia in Parkinson disease

  2004cited by this paper
• A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function.

  2004cited by this paper
• Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.

  2004cited by this paper
• Dual effect of cannabinoid CB1 receptor stimulation on a vanilloid VR1 receptor-mediated response

  2003cited by this paper
• Presynaptic Facilitation of Glutamatergic Synapses to Dopaminergic Neurons of the Rat Substantia Nigra by Endogenous Stimulation of Vanilloid Receptors

  2003influential reference
• Modulation of anxiety through blockade of anandamide hydrolysis

  2003cited by this paper
• Loss of bidirectional striatal synaptic plasticity in L-DOPA–induced dyskinesia

  2003influential reference
• Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa‐induced dyskinesias

  2003cited by this paper
• Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease

  2003cited by this paper
• Anandamide and vanilloid TRPV1 receptors

  2003cited by this paper
• Oxidative metabolism of endocannabinoids.

  2002cited by this paper
• Experimental Parkinsonism Alters Endocannabinoid Degradation: Implications for Striatal Glutamatergic Transmission

  2002cited by this paper
• Pharmacological characterization of the anandamide cyclooxygenase metabolite: prostaglandin E2 ethanolamide.

  2002cited by this paper
• Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway.

  2002cited by this paper
• Brain monoglyceride lipase participating in endocannabinoid inactivation

  2002cited by this paper
• Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease

  2002influential reference
• Animal models of neurological deficits: how relevant is the rat?

  2002cited by this paper
• Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: A pilot study

  2001cited by this paper
• The Activity of Anandamide at Vanilloid VR1 Receptors Requires Facilitated Transport across the Cell Membrane and Is Limited by Intracellular Metabolism*

  2001cited by this paper
• Unawareness of dyskinesias in Parkinson's and Huntington's diseases

  2001cited by this paper
• Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease

  2000cited by this paper
• New perspectives on enigmatic vanilloid receptors.

  2000cited by this paper
• The endocannabinoid system as a target for therapeutic drugs.

  2000cited by this paper
• The spectrum of levodopa-induced dyskinesias.

  2000cited by this paper
• Reversal of Dopamine D2 Receptor Responses by an Anandamide Transport Inhibitor

  2000cited by this paper
• Anandamide - the other side of the coin.

  2000cited by this paper
• Are cannabinoids endogenous ligands for the VR1 capsaicin receptor?

  2000cited by this paper
• Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human.

  2000cited by this paper
• Dopamine activation of endogenous cannabinoid signaling in dorsal striatum

  1999cited by this paper
• Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.

  1998cited by this paper
• The capsaicin receptor: a heat-activated ion channel in the pain pathway

  1997cited by this paper
• The cannabinoid agonists WIN 55,212-2 and CP 55,940 attenuate rotational behavior induced by a dopamine D1 but not a D2 agonist in rats with unilateral lesions of the nigrostriatal pathway.

  1995cited by this paper
• The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behavior: role of nigrostriatal dopaminergic neurons.

  1995cited by this paper
• Effect of bilateral 6-OHDA lesions of the substantia nigra on locomotor activity in the rat.

  1994cited by this paper
• Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenon.

  1992cited by this paper
• The Rat Brain in Stereotaxic Coordinates

  1983influential reference
• AChE-stained horizontal sections of the rat brain in stereotaxic coordinates.

  1980cited by this paper

• Development of cannabinoid-based therapies for Parkinson’s disease: emphasis on targeting cannabinoid receptors as CB2, PPAR-γ and GPR55 receptors

  2026cites this paper
• Cannabinoid receptor 1 ligands: Biased signaling mechanisms driving functionally selective drug discovery.

  2025cites this paper
• Cannabinoid Receptor 1: The Neural Gatekeeper of Health and Disease.

  2025cites this paper
• Research Progress on the Treatment of Peripheral Neuropathy in Multiple Myeloma with Mongolian and Western Medicine

  2025cites this paper
• Cannabidiol improves L-DOPA-induced dyskinesia and modulates neuroinflammation and the endocannabinoid, endovanilloid and nitrergic systems.

  2025cites this paper
• The cannabinoid CB2 receptor: improvement of sleep or memory in rotenone model of Parkinson's disease.

  2025cites this paper
• Brain TRPV1 channel-mediated calcium influx: the immunomodulatory pathway of acupuncture in neuroinflammation

  2025cites this paper
• The Inhibition of Fatty Acid Amide Hydrolase-4 Affords Neuroprotection in a Toxic Model Induced by 6-Hydroxydopamine in Caenorhabditis elegans Nematodes

  2025influential citation
• The Use of Compounds Derived from Cannabis sativa in the Treatment of Epilepsy, Painful Conditions, and Neuropsychiatric and Neurodegenerative Disorders

  2024cites this paper
• CBD’s potential impact on Parkinson’s disease: An updated overview

  2024cites this paper
• 4'-fluorocannabidiol associated with capsazepine restrains L-DOPA-induced dyskinesia in hemiparkinsonian mice: Contribution of anti-inflammatory and anti-glutamatergic mechanisms.

  2024cites this paper
• Cannabinoids in Medicine: A Multifaceted Exploration of Types, Therapeutic Applications, and Emerging Opportunities in Neurodegenerative Diseases and Cancer Therapy

  2023cites this paper
• Levodopa-Induced Dyskinesias in Parkinson’s Disease: An Overview on Pathophysiology, Clinical Manifestations, Therapy Management Strategies and Future Directions

  2023cites this paper
• Levodopa therapy for Parkinson's disease

  2023cites this paper
• Mitochondrial dysfunction and neurological disorders: A narrative review and treatment overview.

  2023cites this paper
• An ensemble docking-based virtual screening according to different TRPV1 pore states toward identifying phytochemical activators

  2023cites this paper
• Machine learning study: from the toxicity studies to tetrahydrocannabinol effects on Parkinson's disease.

  2023cites this paper
• Impact of TRPV1 on Pathogenesis and Therapy of Neurodegenerative Diseases

  2023cites this paper
• Protective Role of Capsaicin in Neurological Disorders: An Overview

  2022cites this paper
• Therapeutic Molecular Insights into the Active Engagement of Cannabinoids in the Therapy of Parkinson’s Disease: A Novel and Futuristic Approach

  2022cites this paper
• What Do We Know About Medical Cannabis in Neurological Disorders and What Are the Next Steps?

  2022cites this paper
• Effects of cannabinoids in Parkinson’s disease animal models: a systematic review and meta-analysis

  2022cites this paper
• Roles of the Cannabinoid System in the Basal Ganglia in Parkinson’s Disease

  2022cites this paper
• INVOLVEMENT OF THE ENDOCANNABINOID SYSTEM IN THE PATHOPHYSIOLOGY AND THERAPEUTICS OF MOVEMENT DISORDERS

  2022cites this paper
• A breakdown in microglial metabolic reprogramming causes internalization dysfunction of α-synuclein in a mouse model of Parkinson’s disease

  2022cites this paper
• Targeting CB2 and TRPV1: Computational Approaches for the Identification of Dual Modulators

  2022cites this paper
• Protective role of endocannabinoid signaling in an animal model of haloperidol-induced tardive dyskinesia.

  2021cites this paper
• Successful and Unsuccessful Brain Aging in Pets: Pathophysiological Mechanisms behind Clinical Signs and Potential Benefits from Palmitoylethanolamide Nutritional Intervention

  2021cites this paper
• The effect of URB597, exercise or their combination on the performance of 6-OHDA mouse model of Parkinson disease in the elevated plus maze, tail suspension test and step-down task

  2021cites this paper
• Collagen VI Regulates Motor Circuit Plasticity and Motor Performance by Cannabinoid Modulation

  2021cites this paper
• Cannabis sativa: Interdisciplinary Strategies and Avenues for Medical and Commercial Progression Outside of CBD and THC

  2021cites this paper
• Bioactive lipids and their metabolism: New therapeutic opportunities for Parkinson's disease

  2021cites this paper
• Circulating fatty acids and endocannabinoidome-related mediator profiles associated to human longevity

  2021cites this paper
• Capsaicin and Dihydrocapsaicin Extracted from Capsicum chinenses Decrease Cell Viability of Neuroblastoma SH-SY5Y Cells In Vitro

  2021cites this paper
• Parkinson's Disease related alterations in cannabinoid transmission.

  2021cites this paper
• Pharmacological and Toxicological Effects of Phytocannabinoids and Recreational Synthetic Cannabinoids: Increasing Risk of Public Health

  2021cites this paper
• Effects of Cannabis in Parkinson’s Disease: A Systematic Review and Meta-Analysis

  2021cites this paper
• Targeting the cannabinoid receptor CB2 in a mouse model of l-dopa induced dyskinesia.

  2020cites this paper
• Therapeutic Potential of Pharmacological Agents Targeting TRP Channels in CNS Disorders.

  2020cites this paper
• Arachidonyl-2'-chloroethylamide (ACEA), a synthetic agonist of cannabinoid receptor, increases CB1R gene expression and reduces dyskinesias in a rat model of Parkinson's disease.

  2020cites this paper
• Endocannabinoid levels in patients with Parkinson's disease with and without levodopa-induced dyskinesias

  2020cites this paper
• Cannabinoids in Neurologic Conditions

  2020cites this paper
• Safety and Tolerability of Cannabidiol in Parkinson Disease: An Open Label, Dose-Escalation Study

  2020cites this paper
• Endocannabinoid levels in patients with Parkinson’s disease with and without levodopa-induced dyskinesias

  2020cites this paper
• Distinctive Evidence Involved in the Role of Endocannabinoid Signalling in Parkinson’s Disease: A Perspective on Associated Therapeutic Interventions

  2020influential citation
• Transient Receptor Potential Channels as an Emerging Target for the Treatment of Parkinson’s Disease: An Insight Into Role of Pharmacological Interventions

  2020cites this paper
• Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson’s Disease

  2020influential citation
• TRPV1 Tunes Optic Nerve Axon Excitability in Glaucoma

  2020cites this paper
• The therapeutic role of cannabinoid receptors and its agonists or antagonists in Parkinson's disease.

  2020cites this paper
• Morpholine derivatives as potential agents for neurological manifestations of nervous system diseases

  2020cites this paper
• Beneficial effects of the phytocannabinoid Δ9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease.

  2020cites this paper
• Minimally Invasive Surgery for Chronic Pain Management: An Evidence-Based Approach

  2020cites this paper
• An investigation into the antidyskinetic and reinforcing effects of UWA-101 in Sprague Dawley rats

  2020cites this paper
• Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson’s Disease and l-DOPA-Induced Dyskinesia

  2019influential citation
• Tat‐Src reduced NR2B tyrosine phosphorylation and its interaction with NR2B in levodopa‐induced dyskinetic rats model

  2019cites this paper
• Is cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms?

  2019cites this paper
• Cannabinoids and the expanded endocannabinoid system in neurological disorders

  2019cites this paper
• Allostatic load and the cannabinoid system: implications for the treatment of physiological abnormalities in post-traumatic stress disorder (PTSD)

  2019cites this paper
• The Rodent Models of Dyskinesia and Their Behavioral Assessment

  2019cites this paper
• Levodopa‐induced dyskinesia in Parkinson disease: Current and evolving concepts

  2018influential citation
• Molecular Imaging of the Cannabinoid System in Idiopathic Parkinson's Disease.

  2018cites this paper
• S-nitrosylation of Src by NR2B-nNOS signal causes Src activation and NR2B tyrosine phosphorylation in levodopa-induced dyskinetic rat model

  2018cites this paper
• Identification of metabolite biomarkers for L‐DOPA‐induced dyskinesia in a rat model of Parkinson’s disease by metabolomic technology

  2018cites this paper
• The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia.

  2018cites this paper
• New approaches and challenges to targeting the endocannabinoid system

  2018cites this paper
• Cannabinoid Modulation of Memory Consolidation in Rats: Beyond the Role of Cannabinoid Receptor Subtype 1

  2017cites this paper
• Control of Motor Function by Adenosine A2A Receptors in Parkinson's and Huntington's Disease

  2017cites this paper
• URB597 reduces biochemical, behavioral and morphological alterations in two neurotoxic models in rats.

  2017cites this paper
• Oxazepam-Dopamine Conjugates Increase Dopamine Delivery into Striatum of Intact Rats.

  2017cites this paper
• The Endocannabinoid System and Parkinson Disease

  2017cites this paper
• Microglial phenotypes in Parkinson's disease and animal models of the disease.

  2017cites this paper
• Capsaicin Protects Against Oxidative Insults and Alleviates Behavioral Deficits in Rats with 6-OHDA-Induced Parkinson’s Disease via Activation of TRPV1

  2017cites this paper
• Cannabis for Basal Ganglia Disorders (Parkinson Disease and Huntington Disease)

  2017cites this paper
• Linking lipid peroxidation and neuropsychiatric disorders: focus on 4-hydroxy-2-nonenal.

  2017cites this paper
• l‐DOPA‐induced dyskinesia and neuroinflammation: do microglia and astrocytes play a role?

  2017cites this paper
• Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target

  2017cites this paper
• Characterization of new antinociceptive ligands in rat model: preclinical studies

  2017influential citation
• Cannabinoids in Parkinson's Disease

  2017influential citation
• N‐oleoyldopamine modulates activity of midbrain dopaminergic neurons through multiple mechanisms

  2017cites this paper
• Capsaicin prevents degeneration of dopamine neurons by inhibiting glial activation and oxidative stress in the MPTP model of Parkinson's disease

  2017cites this paper
• The Endocannabinoid System and Human Brain Functions: Insight From Memory, Motor, and Mood Pathologies

  2017cites this paper
• Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy

  2016cites this paper
• Selective Estrogen Receptor Modulators: Cannabinoid Receptor Inverse Agonists with Differential CB1 and CB2 Selectivity

  2016cites this paper
• Palmitoyl Serotonin Inhibits L-dopa-induced Abnormal Involuntary Movements in the Mouse Parkinson Model

  2016cites this paper
• Repetitive transcranial magnetic stimulation (rTMS) improves behavioral and biochemical deficits in levodopa-induced dyskinetic rats model

  2016cites this paper
• Polymodal Transient Receptor Potential Vanilloid Type 1 Nocisensor: Structure, Modulators, and Therapeutic Applications.

  2016cites this paper
• Cannabinoid–dopamine interactions in the physiology and physiopathology of the basal ganglia

  2016influential citation
• Behavioral evidence for the interaction between cannabinoids and Catha edulis F. (Khat) in mice.

  2016cites this paper
• Multi-Functional Diarylurea Small Molecule Inhibitors of TRPV1 with Therapeutic Potential for Neuroinflammation

  2016cites this paper
• Drugs of abuse and Parkinson's disease.

  2016cites this paper
• Slow synaptic transmission mediated by TRPV1 channels in CA3 interneurons of the hippocampus.

  2016cites this paper
• In vivo characterization of a novel dopamine D3 receptor agonist to treat motor symptoms of Parkinson's disease.

  2016cites this paper
• The bright side of psychoactive substances: cannabinoid-based drugs in motor diseases

  2016cites this paper
• Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease.

  2016cites this paper
• Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders.

  2016cites this paper
• Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: Possible mechanism of action.

  2016cites this paper
• Cannabinoids and Motor Control of the Basal Ganglia: Therapeutic Potential in Movement Disorders

  2016cites this paper
• l‐DOPA‐induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?

  2016cites this paper
• TRPV1 on astrocytes rescues nigral dopamine neurons in Parkinson's disease via CNTF.

  2015cites this paper
• NR2B antagonist CP-101,606 inhibits NR2B phosphorylation at tyrosine-1472 and its interactions with Fyn in levodopa-induced dyskinesia rat model.

  2015cites this paper